Abstract:Graft versus host disease (GVHD) is caused by infused donor T cells that primarily target specific organs, such as skin, liver and intestine. While it has been demonstrated that chemokines are critical to directing in vivo trafficking of host-reactive donor T cells into GVHD target organs, blocking GVHD using antagonist antibody (Ab) against chemokine receptors remains an elusive goal. We found that in vivo administration of anti-CXCR3 Ab for 1 week (named short-term treatment) only partially prevented acute GVHD in B6/SJL mice receiving donor C3H.SW naïve CD8+ T cells, with 45% of them dying from the disease. Flow cytometry analysis showed that CXCR3+ CD8+ T cells occurred in the spleens and livers of these GVHD B6/SJL mice by day 3 and peaked by day 7 after transplantation, and persisted throughout the disease course. When donor CXCR3+ CD8+ T cells were recovered from these GVHD B6/SJL recipients at day 14 after transplantation (named day-14 CXCR3+ CD8+ T cells) and adoptively transferred into secondary B6/SJL mice, they caused severe GVHD in these secondary recipients with 90% mortality. Interestingly, short-term treatment using anti-CXCR3 Ab protected 78% of B6/SJL mice receiving these donor day-14 CXCR3+ CD8+ T cells. Thus, besides CXCR3+ T cells, some other pathogenic T cells have developed during GVH reactions. We found that a substantial population of CXCR3− CD8+ T cells occurred by day 14 (termed day-14 CXCR3− CD8+ T cells) after transplantation in the spleens (71.1%) and livers (81.6%) of B6/SJL recipients with ongoing GVHD. As compared to donor day-14 CXCR3+ CD8+ T cells, donor day-14 CXCR3− CD8+ T cells expressed lower levels of CCR2, CCR3, CCR5, CD127, granzyme B and FasL, and produced less IFN-g and TNF-a. Furthermore, adoptive transfer of donor day-14 CXCR3− CD8+ T cells caused delayed onset of GVHD as compared to those recipients of day-14 CXCR3+ CD8+ T cells, with 55% of them dying from the diseases. Prolonged treatment of B6 mice receiving day-14 CXCR3− CD8+ T cells with anti-CXCR3 Ab up to 3 weeks (named long-term treatment) significantly inhibited the development of GVHD. More than 70% of these recipients survived without clinical signs of GVHD. In vivo experiments showed that 23% of day-14 CXCR3− CD8+ T cells were converted into CXCR3+ by 12 hours after adoptive transfer into B6/SJL recipients, and up to 60% by 24 hours. Interestingly, about 25% of CXCR3+ CD8+ T cells were also converted into CXCR3− by 24 hours after their transfer. We found in ex vivo cultures that both dendritic cells and interleukin-2 accounted for this conversion between CXCR3+ and CXCR3− subsets, which was inhibited by addition of Ab specific to MHC-I or CTLA-4 Ig. Taken together, these results suggest that alloantigen-induced repression of chemokine receptor(s) may present a major barrier to the success of GVHD prevention and treatment when using antagonists against chemokines or chemokine receptors.

Memory T cells migrate to and reject vascularized cardiac allografts independent of the chemokine receptor CXCR3.

Donor IL-6 Deficiency Evidently Reduces Memory T Cell Responses in Sensitized Transplant Recipients.

Down Regulation Of Cxc Chemokine Receptor 3 Impedes The Ability Of Anti-Cxcr3 Antibody To Block Graft-Versus-Host Disease

Endogenous memory CD8 T cells directly mediate cardiac allograft rejection

Cognate antigen directs CD8+ T cell migration to vascularized transplants.

CXCL9 and CXCL10 Accelerate Acute Transplant Rejection Mediated by Alloreactive Memory T Cells in a Mouse Retransplantation Model

Effect of CD4+ Memory T Cells on Rejection Response of Ectopic Heart Transplantation in Mice.

The Major Histocompatibility Complex (MHC) of the Secondary Transplant Tissue Donor Influences the Cross-Reactivity of Alloreactive Memory Cells.

Prior viral infection primes cross-reactive CD8+ T cells that respond to mouse heart allografts

Combination of C-X-C motif chemokine 9 and C-X-C motif chemokine 10 antibodies with FTY720 prolongs the survival of cardiac retransplantation allografts in a mouse model

Memory T-cell-specific therapeutics attenuate allograft rejection via mediation of alloreactivity in memory cells

Cardiac Allograft Tolerance Induced by Isogeneic CD4+CD25+ Regulatory T Cells.

Inhibition of C-X-C Motif Chemokine 10 Reduces Graft Loss Mediated by Memory CD8(+) T Cells in a Rat Cardiac Re-Transplant Model

Blockade of CD27/CD70 Pathway to Reduce the Generation of Memory T Cells and Markedly Prolong the Survival of Heart Allografts in Presensitized Mice

Alloreactive memory CD4 T cells promote transplant rejection by engaging DCs to induce innate inflammation and CD8 T cell priming

Skin and heart allograft rejection solely by long-lived alloreactive T RM cells in skin of severe combined immunodeficient mice

[Roles of CXCL9 and CXCL10 in Acute Rejection after Retransplantation in Mice].

Inactivation Of T-Cell Receptor-Mediated Integrin Activation Prolongs Allograft Survival In Amap-Deficient Mice

Vulnerability of allografts to rejection by MHC class II-restricted T-cell receptor transgenic mice.

Deletion of Smad3 Improves Cardiac Allograft Rejection in Mice.

Single-Cell RNA sequencing reveals immune cell dynamics and local intercellular communication in acute murine cardiac allograft rejection